

IN THE CLAIMS:

Please cancel claims 1, 3 and 19 without prejudice or disclaimer to the subject matter
✓ contained therein.

In accordance with 37 C.F.R. § 1.121, please substitute for claims 2, 4-6, 11 and the second claim 12, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made".

B3 2. (Amended) The nucleic acid molecule of claim 11, where the nucleic acid molecule is purified from a mammal.

Sub C1 4. (Amended) A nucleic acid probe for the detection of a nucleic acid molecule in a sample, wherein said nucleic acid molecule encodes a FRS2 polypeptide comprising at least 10 contiguous amino acids of SEQ ID NO: 1.

B4 5. (Amended) A nucleic acid vector comprising the nucleic acid probe of claim 4 and a promoter effective to initiate transcription in a host cell.

6. (Amended) A recombinant cell or tissue comprising the nucleic acid probe of claim 4.

Sub C2 11. (Amended) An isolated, enriched, or purified nucleic acid molecule comprising a nucleotide sequence that:

B5 (a) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO: 1;

(b) is the complement of the nucleic acid sequence of (a);

(c) encodes a FRS2 polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1;

(d) encodes a FRS2 polypeptide having the full length amino acid sequence of the sequence set forth in SEQ ID NO: 1 except that it lacks one or more of the following segments of amino acid residues: 1-10, 11-152, or 153-508;

(e) is the complement of the nucleic acid sequence of (d);

(f) is a polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 from amino acid residues 1-10, 11-152, or 153-508;

(g) is the complement of the nucleic acid sequence of (f);

B5
cont
(h) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO: 1 except that it lacks one or more of the domains selected from the group consisting of a myristylation region, a phosphotyrosine binding region, and a C-terminal region;

(i) the complement of the nucleic acid sequence of (h);

(j) encodes a polypeptide as set forth in (a), (d), or (f) containing one or both of the following mutations: tyrosine 349 to phenylalanine or tyrosine 392 to phenylalanine; or

(k) the complement of the nucleic acid sequence of (j).

B6
13. (Amended) A recombinant cell or tissue comprising a nucleic acid molecule of claim 11.

REMARKS

Status of the Claims

By this amendment, claims 1, 3 and 19 are canceled and claims 2, 4-6 and 11 are amended. Accordingly, upon entry of this Amendment, claims 2, 4-6 and 11-13 will remain pending in the application. Applicants reserve the right to pursue the subject matter of the canceled claims in subsequent divisional applications. The cancellation of claims does not constitute acquiescence in the propriety of any rejection set forth by the Examiner.